3 terminated. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Terminated 3 |
Follow magrolimab: new trials by email Literature Review of magrolimab trials Research Report on magrolimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia Magrolimab, Venetoclax, Azacitidine - Acute Myeloid Leukemia | Phase 3 | Terminated | Gilead Sciences | 378 | 2022-07-07 | 2025-04-04 |
| Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated Magrolimab, Venetoclax, Azacitidine - Acute Myeloid Leukemia | Phase 3 | Terminated | Gilead Sciences | 258 | 2021-07-01 | 2025-02-05 |
| Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) Magrolimab, Azacitidine, Placebo - Myelodysplastic Syndromes | Phase 3 | Terminated | Gilead Sciences | 539 | 2020-09-09 | 2024-06-27 |
Leukemia, Myeloid, Acute (2) · Myelodysplastic Syndromes (1)
Gilead Sciences (3)
Australia (3) · Austria (3) · Belgium (3) · Canada (3) · France (3) · Germany (3) · Hong Kong (3) · Italy (3) · Spain (3) · Switzerland (3) · United Kingdom (3) · United States (3) · Czechia (2) · Hungary (2) · Netherlands (2)
PMID 37703506, PMID 36888930, PMID 40009500, PMID 40233321, PMID 42441929